All In Biotech

Free tool

FAERS Monitor: Robaxin

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 011790 or its brand name (Robaxin, Methocarbamol). Reports on generic versions are filed under their own applications.

Reports

23,216

Serious

14,376

62% of reports

Hospitalization

6,997

Death reported

1,762

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pain1,771
  • nausea1,717
  • fatigue1,706
  • drug ineffective1,553
  • headache1,339
  • diarrhoea1,232
  • fall1,119
  • dyspnoea1,086
  • arthralgia1,068
  • off label use1,034
  • dizziness985
  • back pain949
  • anxiety928
  • vomiting887
  • depression834

Reports by year received

View as table
YearReports
2004181
2005231
2006235
2007164
2008198
2009297
2010384
2011433
2012585
2013579
2014645
20151,189
20161,584
20171,296
20181,504
20191,679
20201,774
20211,427
20221,493
20231,504
20241,716
20252,253
20261,865

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,030,943 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
back painSignal9493.73.51,891
depressionSignal8343.33.11,367
fallSignal1,1193.12.91,562
anxietySignal9283.02.81,215
painSignal1,7712.62.51,815
arthralgiaSignal1,0682.32.2824
fatigue1,7062.01.9866
nausea1,7172.01.9846
headache1,3391.91.8623
dizziness9851.81.7351
dyspnoea1,0861.71.6349
diarrhoea1,2321.71.6390
vomiting8871.71.6267
off label use1,0341.11.05
drug ineffective1,5531.11.07

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.